Form 4: Chemours Director Livingston Satterthwaite Acquires Shares

Director Livingston Satterthwaite acquired 7,182 stock units in The Chemours Company as part of board compensation.

Summary

• Director Livingston Satterthwaite acquired 7,182 stock units of Chemours Co (CC) on May 6, 2026.
• The acquisition was granted at a price of $0 per share, representing stock units that convert to common stock upon separation from the Board.
• Following this transaction, the director's total beneficial ownership increased to 30,807.855 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Increased alignment between board members and shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The stock units are scheduled to convert one-for-one to Chemours common stock upon the director's separation from service on the Board.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices designed to incentivize long-term board commitment and align director interests with those of public shareholders.

Comparison to Industry Standards

• The use of deferred stock units for board compensation is consistent with standard practices among S&P 500 chemical and industrial companies.

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation structure.

Next Steps

• Conversion of stock units to common stock upon the director's future separation from the Board.

Key Dates

Keywords

Chemours, CC, Insider Trading, Form 4, Director Compensation, Equity Ownership